Trade

Dr Reddy's Laboratories share price

Balanced risk
  • 26%Low risk
  • 26%Moderate risk
  • 26%Balanced risk
  • 26%High risk
  • 26%Extreme risk
  • ₹1,293.00(-1.06%)
    May 8, 2026 15:29:47 PM IST
    • NSE
    • BSE
  • Vol : 1.00 M (NSE + BSE)
    Last 20 day avg : 3.27 M

Dr Reddy's Laboratories is trading -1.06% lower at Rs 1,293.00 as compared to its last closing price. Dr Reddy's Laboratories has been trading in the price range of 1,308.40 & 1,290.25. Dr Reddy's Laboratories has given 2.85% in this year & -1.67% in the last 5 days. Dr Reddy's Laboratories has TTM P/E ratio 19.01 as compared to the sector P/E of 24.71.There are 38 analysts who have initiated coverage on Dr Reddy's Laboratories. There are 6 analysts who have given it a strong buy rating & 11 analysts have given it a buy rating. 8 analysts have given the stock a sell rating.The company posted a net profit of 1,209.90 Crores in its last quarter.Listed peers of Dr Reddy's Laboratories include Lupin (-3.33%), Torrent Pharmaceuticals (0.40%), Divi's Laboratories (0.12%).The Mutual Fund holding in Dr Reddy's Laboratories was at 13.19% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Dr Reddy's Laboratories was at 21.14% in 31 Mar 2026. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on May 10, 2026, 08:57 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.45
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.14
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.61
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    0.52
    Indicates undervaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
1,290.25
Highest
1,308.40
52 week range
Lowest
1,121.20
Highest
1,377.95
Dr Reddy's Laboratories News
Dr Reddy's Laboratories Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Lupin
Bullish
2,377.90-3.331,08,679.4828.785.590.5711.80
Torrent Pharmaceuticals
Bullish
4,376.450.401,48,363.1767.3217.10.8317.62
Divi's Laboratories
Bullish
6,708.900.121,78,626.7178.6111.520.460.01
Cipla
Neutral
1,347.70-1.111,09,012.8522.953.870.870.81
Sun Pharmaceutical Industries
Bullish
1,847.300.704,43,968.9836.245.770.92-
Mutual Fund Ownership
View all
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 531.78
  • % of AUM 9.66
PGIM India Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 6.87
  • % of AUM 6.31
Bandhan BSE Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.09
  • % of AUM 5.99
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 8.73
  • % of AUM 5.58
Nippon India Pharma Fund - Growth
NA
  • Amount Invested (Cr.) 458.22
  • % of AUM 5.49
Dr Reddy's Laboratories Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-05-12Audited Results
2026-01-21Quarterly Results
2025-10-24Quarterly Results
2025-05-09Audited Results, Dividend & Others
2025-01-23Quarterly Results
About the company Dr Reddy's Laboratories
  • IndustryBiotechnology & Drugs
  • ISININE089A01031
  • BSE Code500124
  • NSE CodeDRREDDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
  • Management Info
  • Kallam ReddyExecutive Chairman of the Board
  • Gunupati PrasadExecutive Co-Chairman, Managing Director
  • Erez IsraeliChief Executive Officer
  • Mannam NarasimhamChief Financial Officer
  • Patrick AghanianChief Executive Officer, European Generics
  • M. RamanaChief Executive Officer, Branded Markets (India and Emerging Markets)
  • Deepak SapraChief Executive Officer - API and Services
  • Phanimitra BChief Digital and Information Officer
  • K. SinghCompliance Officer, Company Secretary, Head - CSR
  • Sushrut KulkarniGlobal Head - Integrated Product Development Organisation
Dr Reddy's Laboratories Share Price FAQs

Dr Reddy's Laboratories is trading at 1293.00 as on Fri May 08 2026 09:59:47. This is -1.06% lower as compared to its previous closing price of 1306.80.

The market capitalization of Dr Reddy's Laboratories is 107899.58 Cr as on Fri May 08 2026 09:59:47.

The average broker rating on Dr Reddy's Laboratories is Hold. The breakup of analyst rating is given below -

  • 6 analysts have given a strong buy rating
  • 11 analysts have given a buy rating
  • 9 analysts have given a hold rating
  • 8 analysts have given a sell rating
  • 4 analysts have given a strong sell rating

The 52 wk high for Dr Reddy's Laboratories is 1377.95 whereas the 52 wk low is 1121.20

Dr Reddy's Laboratories can be analyzed on the following key metrics -

  • TTM P/E: 19.01
  • Sector P/E: 24.71
  • Dividend Yield: 0.61%
  • D/E ratio: -

Dr Reddy's Laboratories reported a net profit of 5655.10 Cr in 2025.

The Mutual Fund Shareholding was 13.19% at the end of 31 Mar 2026.

Quick Links
EQUITY QUICK LINKS
Dr Reddy's Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Home/Market/Market Stats/  Dr Reddy's Laboratories share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.